A new reliable blood marker reveals the extent of Alzheimer’s pathology in the brain

Source: https://www.lunduniversity.lu.se/article/new-reliable-blood-marker-reveals-extent-alzheimers-pathology-brain Parent: https://www.lunduniversity.lu.se/research-and-innovation/focus-areas/strategic-research-areas/neuroscience

På svenska

By tove [dot] smeds [at] med [dot] lu [dot] se (Tove Smeds) - published 31 March 2025

Professor Oskar Hansson, professor in neurology at Lund University. Photo: Tove Smeds

Researchers at Lund University and Washington University have identified a blood marker that reflects the amount of Alzheimer’s pathology in the brain. This discovery may play a key role in determining who is most likely to benefit from the new Alzheimer’s drugs.

In brief:

A newly discovered blood marker, MTBR-tau243, can reveal how much Alzheimer’s disease pathology is present in the brain. The higher the level, the more extensive the pathology.
This insight will be critical in distinguishing whether a patient’s symptoms are due to Alzheimer’s disease or another condition. It will also help identify individuals most likely to benefit from the new drugs approved in countries such as the US, Japan and China – with approvals anticipated soon in Europe.

The study was co-led by Professor Oskar Hansson of Lund University and Professor Randall J. Batemanof Washington University School of Medicine. Together, they identified MTBR-tau243, a protein that indicates the level of Alzheimer’s disease in the brain. The discovery could significantly enhance diagnostic accuracy in clinical practice and aid in evaluating the effectiveness of Alzheimer’s treatments.

Lund University had previously shown that the biomarker P-tau217 can detect Alzheimer’s disease up to 20 years before symptoms appear. However, this marker does not reflect how far the disease has progressed. As a result, a patient with cognitive symptoms who tests positive for P-tau217 may be diagnosed with Alzheimer’s even if their current symptoms are due to another cause – although they might develop Alzheimer’s symptoms later.

“This could pose major challenges for patients,” explains Professor Hansson. “That’s why researchers have been searching for a blood marker that appears later in the disease course, when symptoms are more pronounced. We’ve now identified MTBR-tau243 as exactly such a marker – one that also provides a clearer picture of how advanced the disease is in the brain. This is the first time such a marker has been measurable in blood. The higher its levels, the more advanced the Alzheimer’s pathology.”

A two-step approach for diagnosis and treatment planning

Looking ahead, P-tau217 and MTBR-tau243 could be used in combination in clinical settings. First, P-tau217would help determine whether a patient has Alzheimer-related changes in the brain. If the result is positive, MTBR-tau243 could then confirm whether the patient’s current symptoms are indeed due to Alzheimer’s disease, or possibly another condition.

These tests will be essential for the global rollout of disease-modifying treatments for Alzheimer’s. That said, a thorough clinical evaluation by a physician will always be necessary before initiating any treatment, emphasises Professor Hansson.

“This blood test clearly identifies Alzheimer’s tau tangles, which is our best biomarker measure of Alzheimer’s symptoms and dementia,” said co-senior author Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology at WashU Medicine.\ \ “In our clinical practice right now, we don’t have easy or accessible measures of Alzheimer’s tangles and dementia, and so a tangle blood test like this can provide a much better indication if the symptoms are due to Alzheimer’s and may also help doctors decide which treatments are best for their patients.”

Publication

Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease, Nature Medicine, 31 Mars 2025, DOI: 10.1038/s41591-025-03617-7

Contact

Oskar Hansson, professor of neurology at Lund University

Profil in Lund University's research portal

Latest news

Link to RSS

[9 Mar 2026

### A drop that saves eyesight in infants

Research shows that eye drops containing cortisone can prevent the development of the very serious eye disease ROP in infants.](https://www.lunduniversity.lu.se/article/drop-saves-eyesight-infants) - [6 Mar 2026

### Industrial policy crucial for the continued development of green steel

Sweden's investments in climate-friendly green steel are a potential driving force for both European competitiveness and energy independence. However, without a sustainable,…](https://www.lunduniversity.lu.se/article/industrial-policy-crucial-continued-development-green-steel) - [2 Mar 2026

### Large forest fire emissions are hidden underground

Researchers at Lund University have produced the most detailed map of carbon emissions from Swedish forest fires to date. The results show that the largest emissions occur below…](https://www.lunduniversity.lu.se/article/large-forest-fire-emissions-are-hidden-underground) - [26 Feb 2026

### New research identifies potential treatment target in fatty liver disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) can cause more serious liver conditions, such as liver failure. A new study, led by Lund University in Sweden,…](https://www.lunduniversity.lu.se/article/new-research-identifies-potential-treatment-target-fatty-liver-disease) - [26 Feb 2026

### Lipid molecules reorganise at drying interfaces

Minor changes in moisture level can promote lipid molecules to reorganise themselves in biomaterial or biomembranes. This can affect how the skin, lungs and tear film protect us…](https://www.lunduniversity.lu.se/article/lipid-molecules-reorganise-drying-interfaces)

All news

More evidence that blood tests can detect the risk of Alzheimer’s

A new study confirms that a simple blood test can reveal whether there is accelerating nerve cell damage in the brain. The researchers analysed neurofilament light protein (NFL) in...

More news